Market Overview

The global Biopsy Guidance System Market in terms of revenue was estimated to be worth USD 1.59 Billion in 2023 and is poised to reach USD 2.64 Billion by 2032, growing at a CAGR of 5.8 % from 2024 to 2032.

Technologies and devices for the biopsy guidance system help medical professionals to acquire tissue samples with accurate accuracy from a specific body area with diagnostic purposes. Biopsy guidance systems are essential in diagnosis to check the diseases, such as inflammatory diseases, infections, and cancer. These tools decrease the chances of complications and improve patient results with an increase in the biopsy process's accuracy and safety.

Drivers of the market includes increased rates of cancer and an ageing population, higher demand for non-invasive procedures, technology advancement, high government program, and COVID.

Among other chronic diseases, a biopsy is one of the most commonly used techniques for diagnosing cancer. It is widely used in the diagnosis of breast, brain, skin, and prostate cancers. The market is growing mainly due to the increasing prevalence of cancer. For instance, it is estimated that about 1.9 million new cases of cancer would be diagnosed in the United States in 2021, according to Cancer.org. As one of the primary prerequisites for the initial diagnosis of cancer is a biopsy guidance system, an increased number of cancer cases are expected to drive market growth across the forecast period.

Minimally invasive biopsy procedures are becoming increasingly popular. Many product and technology categories, such as vacuum-assisted core biopsy systems, robot-assisted biopsy guiding systems, and needle-based biopsy guns, are expected to experience significant growth over the course of the forecast period. For example, IZI Medical Products, LLC unveiled the Quick-Core Auto Biopsy System for soft tissue biopsy in March 2021. This is a light, totally automatic biopsy device that is precise, high-quality, and reliable. Moreover, an increasing level of awareness among patients and healthcare professionals with respect to the detection and treatment of breast cancer during the projection period is expected to positively impact market growth.

Market Drivers

Increasing Incidence of Cancer and Chronic Diseases

The rising diagnosis of cancer and other chronic diseases has highly increased the demand for accurate diagnostic equipment in the health field. In this regard, biopsy guiding systems are of importance because they will be needed to obtain tissue samples that are required in the determination of most diseases, especially cancer. They enable physicians to precisely locate lesions and tumours, which mean more accurate biopsies by ensuring samples obtained from patients, are typical of the involved tissue. This is important, especially in oncology cases; any delay or mistake will definitely impact the choice and effect of treatment.

Advances in imaging technologies, such as ultrasound, CT, and MRI, make it possible to create biopsy guiding systems allowing real-time visualization during procedures that minimize the risk of complications and increase patient safety. Finally, as attention to personalized medicine and earlier diagnosis becomes even more intense, the ability to obtain tissue samples which exactly and accurately represent the lesion will become much more critical in tailoring a specific treatment regimen for each patient. The growing rate of chronic diseases and cancer points, therefore, to the importance of biopsy guiding systems in modern diagnostics, as well as their application in any fields of medical specialty, and general standards of patient care.

Key Findings

• One of the leading companies in medical technology, Becton, Dickinson, and Company, unveiled a new robotic track system for the BD Kiestra microbiological lab solution in January 2023. Automated specimen processing in lab settings is made possible by this creative approach.
• The global medical technology company Trivitron Healthcare acquired a 100% stake in The Kennedy Company (US), a leading manufacturer of X-ray shielding material for radiation protection and acoustic barriers, in March 2022. This would help Trivitron supply Breast Biopsy products to the customers of US-based businesses that it has purchased.

Market Opportunities

Growing Importance of Early Diagnosis

The demand for effective diagnostic devices is increasing rapidly with every person who learns about the merits of early disease detection. For instance, in the treatment of diseases, especially cancers, which are conditions where treatment in time can significantly contribute to patient recovery, an early diagnosis is very significant. In this regard, biopsy guiding devices play a crucial role as they enable doctors to retrieve accurate tissue samples for diagnostic studies. These devices allow the exact localization of abnormalities with the aid of the most up-to-date imaging technologies including ultrasound, CT, and MRI. This helps doctors perform biopsies that are less invasive yet precise. Other than making these procedures less risky, it is also more likely that a disorder will be caught when the chances of treatment are the best. This is because of the exact and timely diagnoses that biopsy guidance systems provide; healthcare providers can make individualized treatment programs that fit the needs of each patient. This, therefore, calls for incorporation into clinical practice because, with an emphasis on the preventive nature of care as well as early intervention of healthcare systems, a better health care environment that accords higher priority to early detection and better patient outcomes at all medical specialties will be promoted.

Market Restraining Factors

Limited Awareness and Training

Lack of knowledge and understanding by the medical practitioners on the benefits of biopsy guided systems is one of the main reasons for their non-acceptance. It may be that most of the medical practitioners are not aware of all the benefits these technologies offer, including increased accuracy in the location of lesions, improved safety for patients, and diagnostic results. This lack of knowledge might lead to reluctance on the part of the medical practitioners in accepting these technologies into clinical practice. This problem can also be worsened by poor education and training regarding the use and care of biopsy guiding systems. Without appropriate training or tools, health care professionals may be unable to use the technology effectively, which may lead to its underutilization or even misuse in procedures. The likelihood of inappropriate use can make these systems less effective and lead to outcomes that are worse than they could be for patients. Over these barriers, health care organizations have to invest heavily in comprehensive training programs and public education on benefits and capabilities of biopsy guiding systems. They can then offer doctors the know-how and abilities they need to use such advanced diagnostic tools appropriately and, therefore, improve patient care and outcomes.

Segmentation Analysis

The market scope is segmented because of by Technology, by Product Type, by Application, by End-User.

By Technology

Based on the Technology of the market is segmented into Ultrasound-Guided Biopsy, CT-Guided Biopsy, MRI-Guided Biopsy, Others.

The ultrasound-guided biopsy is the most dominant application in the biopsy guidance system market due to its adaptability, real-time vision, and effectiveness in targeting lesions in soft tissues. Clinicians can precisely guide a biopsy needle to the lesion with minimal damage to other tissues using ultrasound technology. It is most frequently utilized in breast biopsies, where ultrasound produces crisp images of soft tissues to enable fast, non-invasive procedures. CT-guided biopsy is another major technique, which is more useful in cases of deep-seated tumours in organs like lungs, liver, and kidneys. The cross-sectional views from the CT images help the clinicians to find the precise location of the tumour and to position the needle in that area with much accuracy—thus, especially useful in inaccessible areas. For instance, CT-guided biopsy is utilized in most cases to diagnose lung lesions since the small nodules can be visualized. MRI-guided biopsy is applied mainly for sensitive areas, which are complex such as brain and prostate areas with a good resolution of the images, without ionizing radiation. Other new techniques such as PET-CT and fusion imaging integrate two or more imaging modalities that facilitate better visualization of diagnostic information.

By Product Type

Based on the Product Type of the market is segmented into Needle Biopsy Systems, Biopsy Instruments, Software Solutions.

The largest segment of the biopsy guidance system market is needle biopsy systems, since these are required to provide tissue samples accurately in various applications of biopsy. The system comprises different types of needles, designed for specific procedures, such as core needle and fine-needle aspiration. It makes core needle biopsy very widely applied in diagnosing solid masses, especially for breast and prostate biopsies, because it takes out a small cylindrical sample of tissue; this means providing significant information on the architecture of the tissue. Fine-needle aspiration employs the aspiration of cells with the aid of a fine needle, being particularly applied for thyroid or lymph node biopsies in cases where a less invasive sample would suffice.

There are biopsy instrumentation tools associated with the entire process like guiding devices that will allow the stabilizing of the positions of the needles, markers that amplify efficiency and accuracy in pointing out such tiny or deeply laid lesions, and there are other stabilizers as well so that the procedure is effectual and safe on the patients. These systems are complemented by software solutions that advance the imaging, planning, and navigation capabilities for highly accurate, tailored procedures. For example, some software allows clinicians to view a 3D image of the biopsy area and, in real time, change the direction in which the needle is sent through the skin. Combining these technologies has improved biopsy accuracy and outcomes for patients.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominates the market due to sophisticated healthcare infrastructures, higher prevalence rates of cancer, and the strong presence of established diagnostics landscapes. Within this region, the United States accounts for the lion's share of the biopsy guidance market due to considerable investments in healthcare technology as well as strong focus on early detection of diseases and precision medicine. Governmental policies and funds, along with funding research and public-private partnership are some factors contributing towards the growth of the biopsy guidance market. Although the market size is much smaller, similar trends occur in Canada based on factors such as aging population and increased awareness regarding cancer screening.

Europe accounts for one of the leading markets of biopsy guidance systems in the global market, with leaders being Germany, the UK, and France. These countries have highly developed and strong reimbursement policies in healthcare, which urges hospitals and diagnostic centres to opt for advanced biopsy technologies. Early detection of cancer and preventive health care are other thrust areas in Europe, where biopsy systems are in increased demand. Cancer awareness programs receive support from both government and non-government organizations, hence increasing market growth.

Asia-Pacific is the fastest-growing region due to rapid growth in healthcare infrastructure, increasing health expenditure, and rising incidence of cancer in China, India, and Japan. China and India have enhanced healthcare facilities and economic growth, thereby enhancing the use of advanced medical technologies. Education campaigns along with government health programs enhance awareness about cancer screening. Therefore, the demand for biopsy guidance systems increases in that region. Japan contributes the most because it is the land of the aging people and more prone to cancers that require regular screenings and biopsies.

Latin America and the Middle East & Africa are emerging markets, which have tremendous growth opportunities. In Latin America, Brazil and Mexico have increased adoption of biopsy systems owing to improved healthcare access and increasing awareness about cancer. However, in some regions, limited funding for healthcare and fewer trained professionals will restrict growth. Demand in the Middle East and Africa is increasing because of urbanization and development in the health sector, mainly in the economically developing countries of the UAE and South Africa. However, lack of access to advanced healthcare and economic constraints might deter growth in the market.

In summary, although North America and Europe are currently at the top of the list for the biopsy guidance system market due to their established healthcare systems and higher prevalence of disease, the Asia-Pacific region will experience the highest growth rate because the investment in healthcare is rising and awareness is increasing. Emerging markets of Latin America and Middle East & Africa have growth potential as well, due to their continually improving healthcare infrastructure and increasing awareness.

List of Companies Profiled:

• Becton, Dickinson, and Company
• Hologic, Inc.
• Devicor Medical Products, Inc.
• Braun Melsungen AG
• ARGON MEDICAL
• Boston Scientific Corporation
• INRAD Inc.
• Cook Medical
• PLANMED OY.

Key Industry Developments

• September 2021 The purpose of the EZ Shot 3 Plus, a fine needle biopsy tool, is to collect superior tissue samples with the least amount of harm to the surrounding tissue.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Biopsy Guidance System Market. The qualitative data includes latest trends, market player’s analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations:

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Biopsy Guidance System market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Biopsy Guidance System. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Biopsy Guidance System companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Biopsy Guidance System Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Biopsy Guidance System Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Biopsy Guidance System Market valued?
• Which region has the largest share in 2021 for the global Biopsy Guidance System Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Biopsy Guidance System Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: